In the current study, we found synergistic cytotoxic effects for combinations of PTC596 with APR-246, S63845, trametinib, in many AML cell lines, including the TP53 double mutant MOLM-16, which turned out to be resistant to various other targeted therapies in the past. Here, TP53 is linked to acute myeloid leukemia.